HRA011539
Title:
The results of APICAL-GC cohort
Release date:
2025-05-17
Description:
Efficacy and safety of anlotinib plus toripalimab as a first-line treatment regimen for advanced gastric cancer in patients with performance status 2 (APICAL-GC): an open-label, single-arm, phase II trial
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Cohort Study
Disease name:
gastrointestinal system cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
The results of APICAL-GC cohort
Contact person:
Liu Ke
Email:
doctorliuke@163.com
Description:
The results of APICAL-GC cohort
Individuals & samples
Submitter:   Liu Dongyu / dongyu.liu@3dmedcare.com
Organization:   3D Medicines Inc.
Submission date:   2025-05-15
Requests:   -